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Objectives: According to World Health Organization, influenza and acute respira-
tory infections (ARI) affect more than 30% of the population each year. In Ukraine the 
burden of costs for medicines are mainly paid by patients out of pocket. MethOds: 
We analyzed the statistics of the Ministry of Health of Ukraine, the incidence of 
influenza and ARI, the Protocol for diagnosis and treatment of novel influenza A 
(H1 / N1) (CA) in adults in Ukraine and used the pharmacoeconomic method «Cost 
of illness». Results: We received that number of outpatients were in 2009-2010 
(Nov- May, Pandemic) - 7,753,635 sick persons, 2010-2011 (Oct 2010 - Apr. 2011) - 
7,502,008, 2011-2012 - 5,584,518, 2012-2013 – 6,200,000, 2013-2014 – 6,015,000, respec-
tively. Based on these data, we found that in 2014 the number of cases decreased 
by almost 1, 5 million compared with 2010. Now we compared the direct costs on 
outpatient treatment in 2014 and 2010. The direct cost per patient of influenza and 
ARI in 2010 amounted to 80,39 UAH. We estimated the total costs were 60386423 
UAH. Direct costs for outpatient costs consist of expenses for medicines and doc-
tor’s consultations. The direct cost per patient of influenza and ARI in 2014 totaled 
221,07 UAH. Cost of Illness was 1329751087 UAH. This situation is connected with 
the rising prices of drugs through the exchange rate in Ukraine in 2014. Financing of 
medicines by 90% are of own patient funds. In Ukraine established the some groups 
which drugs are dispensed free of charge or concessional. They represent the range 
of 10% of all patients. cOnclusiOns: High costs for treatment of influenza and 
ARI should reimburse by state and it’s need the monitoring the incidence and to 
evaluate indirect costs.
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Objectives: Malaysia is experiencing an escalation of dengue epidemic activity. 
The candidate vaccine currently at the most advanced stage of development has 
demonstrated its efficacy in two large scale efficacy studies. This study aims to 
estimate the potential health and economic impact of the vaccine in Malaysia 
under different vaccination strategies. MethOds: A dengue dynamic transmis-
sion mathematical model was employed to evaluate the impact of dengue vaccina-
tion program on the incidence, mortality and economic burden of the disease. The 
model was calibrated and validated with Malaysia specific epidemiological data 
and vaccine efficacy data from phase-III efficacy studies. The impact was evalu-
ated over a 10-year period from provider perspective. Two vaccination strategies, 
targeted-hotspots (THS, covered population in 6 selected hotspot districts) and 
nationwide (NW, covered the whole Malaysian population), were simulated. Both 
strategies comprised of routinely vaccinated children aged 13 and a catch-up 
cohort from ages 14 to 30 who were vaccinated over a 1 year duration. Probabilistic 
and univariate sensitivity analyses on key parameters were conducted to examine 
uncertainty in the model. All costs were expressed in 2013 USD. Results: The cost 
per dengue case from provider perspective was USD999.02. The model predicted 
that dengue vaccination under the THS strategy would prevent 448,124 [95%CI: 
292,875; 632,375] dengue cases, 509 [95%CI: 335; 707] dengue-related deaths, 11,785 
[95%CI: 7,888; 16,329] life years lost and 16,751 [95%CI: 11,128; 23,281] DALYs. 
Nationwide vaccination would prevent 1,060,222 [95%CI: 694,181; 1,490,929] den-
gue cases, 1,202 [95%CI: 797; 1,672] dengue-related deaths, 27,834 [95%CI: 18,756; 
38,501] life years lost and 39,584 [95%CI: 26,464; 54,968] DALYs. The total dengue 
treatment cost saved for THS and NW vaccination strategy were USD163,859,846 
[95%CI: 109,093,124; 235,805,776] and USD386,962,641 [95%CI: 257,410,189; 
557,347,377] respectively. cOnclusiOns: We conclude that dengue vaccination 
would significantly reduce the disease and economic burden in Malaysia, espe-
cially if it is introduced during current dengue epidemic.
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Objectives: Outpatient parenteral antimicrobial therapy (OPAT) is a strategic 
delivery modality of care however cost-analysis should support decision-making. 
This study was performed in order to analyze the economic studies related to 
OPAT MethOds: a systematic review was performed with the following search 
terms: outpatient (Population), anti-infective agents, infusion therapy or home care 
(Intervention), inpatient (Comparator), complications related to infection, cure, read-
mission, catheter infection, death (Outcome), and economic analysis (Study design). 
Publications were searched from health sciences databases (MEDLINE, Embase, 
The Cochrane Library, Lilacs, Bireme, Medscape, Trip database, Web of Science), 
health technology evaluation sites and gray literature (dissertation abstracts), inde-
pendently of publication´s year or idiom. Three different reviewers evaluated the 
manuscripts in a systematic progressive process beginning from title followed by 
abstract and complete reading for quality of evidence. Results: 655 publications 
were identified according to PICOS proposed. Of this, 9 studies developed in eight 
different countries, from 2001 to 2014, were included for analysis. OPAT regimen 
was based on infusion center at five (combined with home care in three) and home 
care exclusively in four studies. The perspective of cost analysis was of the hospital 
by seven sites, health care system in one, hospital combined to health care system 
in one and payer by the other one. The type of analysis was cost-consequence in 
Objectives: To estimate the annual average per patient cost for diagnosing and 
treating chronic hepatitis B (CHB) and its complications in three large metropoli-
tan cities in India. MethOds: Health resources consumed during the diagnosis 
and treatment of CHB and its complications were estimated by administering a 
structured survey to a total of 30 participating physicians from 3 cities (8 hepa-
tologist/gastroenterologist and 2 oncologist treating hepatocellular carcinoma 
patients per city). Equal number of physicians from private and central govern-
ment health scheme hospitals (CGHS) participated in the survey. Cost for labora-
tory tests, imaging, procedures, hospital admissions, physician visits, and drugs 
received on an inpatient and outpatient basis were estimated using rates provided 
by private setting centres and CGHS approved rates in the 3 cities. Mean, median, 
standard deviation, and frequency were used to analyze data. Results: Total 
annual average cost for treating CHB, compensated cirrhosis, decompensated 
cirrhosis, and hepatocellular carcinoma (HCC) were INR 79,768 (USD 1,269), INR 
53,223 (USD 846), INR 3,99,316 (USD 6,355), and INR 5,069,12 (USD 8,067) in a pri-
vate hospital and INR 49,796 (USD 792), INR 33,976 (USD 538), INR 2,73,564 (USD 
4,353), and INR 358,071 (USD 5,698) in a CGHS hospital, respectively. The added 
inpatient cost of undergoing liver transplant for eligible HCC patients was on 
an average INR 25,00,000 (USD 39,783). cOnclusiOns: Findings from our study 
provide an initial understanding of the magnitude of direct medical cost burden 
that CHB and its complications impose on patients in India. The results high-
light the increasing health-care cost related to disease progression which can 
be potentially reduced by effective prevention strategies, early treatment, and 
patient education to improve adherence to treatment. Future efforts should focus 
on conducting large observational studies using patient level data and develop 
models to support uptake of cost-effective strategies to manage the burden of CHB 
in India.
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Objectives: The aim of this study was to estimate health and medical care costs 
for hospitalized pneumonia among children < 2 years of age, pre- and post the 
introduction of Prevenar13 (PCV13) in Sweden. MethOds: The incidence of inpa-
tient all-cause pneumonia (ICD-10 J12-J18) by County Council among children 
< 2 years old between 1998 and 2013 was identified using the Swedish National 
Inpatient Register. The average incidence of pneumonia was calculated among 
County Councils that were utilizing PCV13 in two periods; the pre PCV period 
(during 1998-2006) and the post PCV 13 period (during 2011-2013). In a subsequent 
step, the average incidence per 100 000 by calendar period was multiplied with 
the expected costs of inpatient pneumonia (34 524 SEK, 3 712 € ) Results: The 
mean rates of all-cause pneumonia hospitalizations per 100,000 person years 
were higher in the pre-PCV13 era compared to after the introduction of PCV13 in 
Sweden (pre-PCV13; 596.4 and post-PCV13; 455.7 per 100,000 person years, respec-
tively). A difference of almost 5 million SEK (538 000€ ), in health and medical care 
costs per 100,000 person years was observed during the pre and post introduc-
tion of PCV13 among County Councils that were utilizing PCV13 between 2011 
and 2013. cOnclusiOns: Among children < 2 years old, all-cause pneumonia 
hospitalizations were reduced after introduction of PCV13 vaccination in Sweden. 
A reduction in the incidence of pneumonia also reduced the health and medical 
care costs.
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Objectives: The aim of this study was (1) to assess the epidemiologic profile of CDI 
in England and Merseyside in the last decade and (2) to estimate the costs associ-
ated with CDI episodes through successive seasons (2008-2012) in a large hospital 
setting (Royal Liverpool & Broadgreen University Hospitals). MethOds: (1) National 
figures for incidence and CDI-associated deaths were obtained from the Office for 
National Statistics and the Public Health England. (2) Clinical and epidemiologi-
cal information was obtained from 397 consecutive CDI and antibiotic-associated 
diarrhoea (AAD) patients assessed by medical staff and recruited by a prospective 
study. Costs were obtained through the determination of hospital stay and the 
most relevant Healthcare-Resource-Group (HRG) recorded for the disease period 
until their discharge/death. Generalised linear models with gamma distribution 
were employed for the multivariate analysis. Results: A CDI epidemic season was 
evident between 2005 and 2010, reaching its peak during the 2007/2008 season fol-
lowing by an endemic phase (2011/2012 onwards). Between 2009-2013 when national 
figures became available, Northern and Western regions displayed the highest inci-
dence and death rates. Within Merseyside, Liverpool had the highest incidence 
of all. Significantly higher incidence rates of CDI were generally correlated with 
index-of-multiple-deprivation (IMD), which was particularly higher in Merseyside 
than the national average. Mean costs for cases were significantly higher (£14,424.07) 
than controls (£3467.25). Pre-test costs and low Albumin levels were statistically 
significant predictor of CDI costs. cOnclusiOns: CDI was indeed associated with 
increased overall hospitalisation costs. However, the extent to which CDI per se pro-
longs hospitalisation remains an objective as comorbidities and underlying condi-
tions (denoted by pre-test costs) were the strongest predictors. Further work is being 
conducted to disentangle the impact of other significant contributing factors, and 
the use of HRGs will be compared to Patient-Level-Information-and-Costs-System 
(PLICS) using a replication set of patients.
